ClinicalTrials.gg
CompletedNCT00134966Updated May 17, 2017

A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa

A Phase 3 interventional study of capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) in Parkinson's Disease, sponsored by Novartis. Completed at 60 sites in 8 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-05-17.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
493
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing carbidopa in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. Carbidopa · Parkinson Disease.

Enrollment
2nd of 24
493 · median 46
Started
2005
with 2 others
Phase 3
7 of 24
none open now
Registered
3rd of 24
by date
Lead sponsor
4 of 24
Novartis

Among the 24 studies testing carbidopa in Parkinson Disease, this one is the 2nd largest by enrollment, is one of 3 that started in 2005, is one of 7 in phase 3, and was the 3rd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 24 studies testing carbidopa in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About carbidopa

Carbidopa: first FDA approval 1975 (SINEMET), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing carbidopa in Parkinson Disease, or all of them as a file.
02

Study summary

The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit than immediate release carbidopa/levodopa administered at the same levodopa dosage level of 100 mg three times a day (t.i.d.).

Read the detailed description

The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit than immediate release carbidopa/levodopa administered at the same levodopa dosage level 100 mg t.i.d.

03

Conditions studied

  • Parkinson's Disease

Keywords

  • Parkinson's disease, levodopa, dyskinesia
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 30 to 80 years, inclusive, at time of Parkinson's disease diagnosis
  • Idiopathic Parkinson's disease with at least 2 cardinal signs of disease: resting tremor, bradykinesia or rigidity
  • Parkinson's disease impairment warranting treatment with a levodopa formulation according to the investigator's assessment

Exclusion criteria

Exclusion Criteria:

  • History, signs or symptoms suggesting the diagnosis of atypical or secondary Parkinsonism due to drugs, metabolic disorders, encephalitis or other neurodegenerative diseases
  • History of stereotaxic brain surgery for PD (e.g., pallidotomy, deep brain stimulation, tissue transplant)
  • Diagnosis of Parkinson's disease for more than 5 years prior to Screening
  • Previous use of levodopa in any formulation, entacapone or tolcapone for more than 30 days or anytime within 4 weeks (28 days) prior to baseline
  • Use of a dopamine agonist within 4 weeks (28 days) prior to baseline
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    1

    Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)

  • Active comparator
    2

    Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)

Interventions

  • Drugcapsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)

    Drug pages: Carbidopa · Levodopa · Entacapone

    Also known as: Stalevo, CELC200

06

What researchers measure

Primary outcomes

  1. Symptom control change from baseline to week 39

Secondary outcomes

  1. Change from baseline to week 39 in activities of daily living

  2. Change from baseline to week 39 in motor function

  3. Change from baseline to week 39 in mental acuity

  4. Change from baseline to week 39 in incidence of dyskinesia and wearing off

07

Study locations

60 sites
  • Barrow Neurology Clinics at St. Joseph's Hosptial & Medical Center
    Phoenix, Arizona 85013, United States
  • Coastal Neurological Medical Group, Inc
    La Jolla, California 92037, United States
  • Neurosearch, Inc.
    Reseda, California 91335, United States
  • University of Florida Health Science Center
    Jacksonville, Florida 32209, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • USF Medical Clinic
    Tampa, Florida 33612, United States
  • Springfield Neurology Associates, LLC
    Springfield, Massachusetts 01104, United States
  • Clinical Neuroscience Center
    Southfield, Michigan 48034, United States
  • Melbourne Internal Medicine Associates
    Westlake, Ohio 44145, United States
  • Westmoreland Neurology Associates, Inc.
    Greensburg, Pennsylvania 15601, United States
  • Lankenau Hospital
    Wynnewood, Pennsylvania 19096-3425, United States
  • NeuroHealth
    Warwick, Rhode Island 02886, United States
  • Coastal Neurology, PA
    Beaufort, South Carolina 29902, United States
  • Senior Adults Specialty Research
    Austin, Texas 78757, United States
  • Baylor College of Medicine, Parkinson's Disease Center
    Houston, Texas 77030, United States
  • Neurology Associates
    San Marcos, Texas 78666, United States
  • Blue Ridge Research Center at Roanoke Neurological Center
    Roanoke, Virginia 24014, United States
  • Heritage Medical Research Clinic
    Calgary, Alberta T2N 4N1, Canada
  • Moncton, New Brunswick E1C 2M4, Canada
  • Eastern Health Care - Health Sciences Centre, Neurology Department
    HSC Room 5317, 300 Prince Philip Drive, St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Neurology Division, Health Science Center
    Halifax, Nova Scotia B3J 3T1, Canada
  • Cape Breton Regional Hospital, Neurology Department
    Sydney, Nova Scotia B1P 1P3, Canada
  • Grand River Hospital
    Kitchener, Ontario N2H 5Z8, Canada
  • London Health Sciences Center, University Hospital, Rm. A10-026
    London, Ontario N6A 5A5, Canada
  • Centre for Movement Disorders
    Markham, Ontario L6B 1C9, Canada
  • Parkinson's & Neurodegenerative Disorders Clinic
    Ottawa, Ontario K1G 4G3, Canada
  • Ottawa Hospital, Civic Campus
    Ottawa, Ontario K1Y 4E9, Canada
  • Hiren Desai Medicine Professional Corporation
    Windsor, Ontario N8X 5A6, Canada
  • Neuro Rive Sud
    Greenfield Park, Quebec J4V 2J2, Canada
  • Montreal General Hospital
    Montreal, Quebec H3G 1A4, Canada
  • Unite des Troubles du Mouvement Andre-Barbeau, CHUM-Hotel-Dieu
    Montreal, Quebec, Canada
  • Centre de Recjerche Clinique du CHUS
    Sherbrooke, Quebec J1H 5N4, Canada
  • Dr. Felix Veloso Research
    Regina, Saskatchewan S4T 1A5, Canada
  • Quebec Memory and Motor Skills Disorders Clinic
    Quebec, G1R 3X5, Canada
  • University of Saskatchewan, Royal University Hospital
    Saskatoon, S7N 0W8, Canada
  • Neurologická klinika, Univerzita Palackého
    I.P.Pavlova 6, Olomouc 775 20, Czechia
  • FN-neurologická klinika
    Alej Svobody 80, Plzeň 304 60, Czechia
  • Neurologicka klinika
    Katerinska 12, Praha 2, 12000, Czechia
  • FN-Nemocnice Pardubice
    Kyjevska 44, Pardubice, 53000, Czechia
  • Rambam Medical Center
    Haliya Hashniya 8, Haifa 31096, Israel
  • Dep. Of Neurology (Bitan 38, EEG institute)
    Dep. Of Neurology, Zerifin, 70300, Israel
  • Belinson Campus, Jabotinsky st. Movement Disorder Unit
    Petach Tikva, 49100, Israel
  • Sourasky Medical Center
    Weitzman St. Movement Disorder Clinic, Tel Aviv, 64239, Israel
  • Clinica Neurologica I - Azienda Ospedaliera-Universitaria Policlinico - Università di Catania
    Via Santa Sofia 78, Catania 95123, Italy
  • "Dipartimento di Neuroscienze Oftalmologia e Genetica (DINOG)
    Università degli Studi di Genova, Via De Toni 5, Genova 16132, Italy
  • Unità Operativa Complessa Neurologia - Policlinico Universitario "G. Martino"
    Via Consolare Valeria, Messina 98125, Italy
  • Istituto Nazionale Neurologico "Carlo Besta"
    Via Celoria 11, Milano 20100, Italy
  • Dipartimento di Neuroscienze-Sezione Neurologia Università degli Studi di Pisa- AO S. Chiara
    Via Roma, 67, Pisa 56127, Italy
  • Dipartimento di Scienze Neurologiche Università degli Studi di Roma "La Sapienza" Roma I
    Viale dell'Università 30, Roma 00185, Italy
  • Dipartimento di Neuroscienze-Università degli Studi di Torino
    Via Cherasco 15, Torino 10126, Italy
  • A.O. Istituti Clinici di Perfezionamento-Unita'Operativa Centro Parkinson
    Via Bignami 1, Milan, 20126, Italy
  • Samodzielny Publiczny Szpital Kliniczny Oddzial Kliniczny Neurologii i Epiletologii
    ul. Czerniakowska 231, Warszawa, 00-416, Poland
  • Centrum Neurologii Klinicznej
    Ul. Dwernickiego 8, Krakow, 31-530, Poland
  • Klinika Neruologii Wieku Podeszlego
    ul.Medykow 14, Katowice, 40-752, Poland
  • Hospitais da Universidade de Coimbra (Serv. Neurologia)
    Avenida Bissaya Barreto, Coimbra, 3000-075, Portugal
  • Hospital de Santa Maria (Serv. Neurologia)
    Avenida Professor Egas Moniz, Lisbon, 1649-035, Portugal
  • Hospital de Santo António (Serv. Neurologia)
    Largo Professor Abel Salazar, Porto, 4099-001, Portugal
  • Istanbul CAPA Medical School
    Istanbul University CAPA Medical School, Dept. of Neurology, Istanbul 34610, Turkey
  • Hacettepe Medical School, Department of Neurology
    Hacettepe Universitesi Hastaneleri Norooji AD Sihhiye, Ankara, 6,100, Turkey
  • Dokuz Eylul Medical School, Department of Neurology
    Noroloji Anabilim Dali Inciralti Izmir, Izmir, 35340, Turkey
08

References and documents

Publications

  • Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A; FIRST-STEP Study Group. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord. 2009 Mar 15;24(4):541-50. doi: 10.1002/mds.22343. PubMed 19058133 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2005
First posted
Aug 25, 2005
Start
Aug 2005
Primary completionActual
Sep 2007
CompletionActual
Sep 2007
Last update
May 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00134966
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Aug 25, 2005
Start date
Aug 2005
Primary completion
Sep 2007
Completion
Sep 2007
Last update
May 17, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carbidopa · Levodopa · Entacapone

Start the discussion